Largest CRISPR & Gene Editing Companies by Market Cap

Emmanuelle Charpentier and Jennifer Doudna won the 2020 Nobel Prize in Chemistry for discovering CRISPR-Cas9 — a gene editing tool that lets scientists cut, delete, or modify specific DNA sequences using a guide RNA and the Cas9 enzyme. The technology, which harnesses a natural bacterial defense mechanism, has since become the most widely used third-generation gene editing system, following earlier approaches like zinc-finger nucleases and TALENs.

CRISPR Therapeutics and partner Vertex Pharmaceuticals secured the first-ever FDA approval for a CRISPR-based therapy — Casgevy (exagamglogene autotemcel) — for the treatment of sickle cell disease. Casgevy was later also approved for transfusion-dependent β-thalassemia, with regulatory clearance from the EMA and UK MHRA as well.

The publicly traded pure-play gene editing companies are concentrated on NASDAQ:

• CRISPR Therapeutics (CRSP): Founded in 2013 by Emmanuelle Charpentier and headquartered in Zug, Switzerland. Programs span hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The only CRISPR-focused biotech that has advanced beyond clinical-stage development.
• Intellia Therapeutics (NTLA): Based in Cambridge, Massachusetts. Focuses on delivering CRISPR/Cas9 systemically into patients using lipid nanoparticles. Published the first human clinical data for an in vivo gene editing therapy with its NTLA-2001 candidate.
• Beam Therapeutics (BEAM): Also in Cambridge, co-founded by David R. Liu and Feng Zhang out of the Broad Institute of MIT and Harvard. Specializes in base editing — rewriting single DNA letters without creating double-strand breaks.
• Editas Medicine (EDIT): Cambridge-based company using CRISPR/Cas9 to develop therapies for genetically determined disorders.

Beyond therapeutics, CRISPR applications extend into agriculture — modifying genes related to disease resistance, yield, and nutritional content — and into diagnostics, where CRISPR-based tests have been developed for rapid infectious disease detection. Next-generation tools like base editing and prime editing continue to expand the technology’s reach. For a broader look at the healthcare sector, see the largest pharmaceutical companies or the largest healthcare companies by market cap.

Regulated broker Invest now: Buy Stocks & ETFs in just 15 minutes from $50 Your capital is at risk. Free demo account & education

The table below ranks the leading publicly traded CRISPR and gene editing companies by market capitalization, with live pricing data.